Thiazolidinediones News and Research

RSS
Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
New biological insights into fat tissue

New biological insights into fat tissue

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

TZDs might serve as new agents for addiction treatment

TZDs might serve as new agents for addiction treatment

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

ChemoCentryx presents CCX140 clinical data at EASD

ChemoCentryx presents CCX140 clinical data at EASD

Use of oral medications for diabetes increases among Americans: Report

Use of oral medications for diabetes increases among Americans: Report

Two diabetes medications increase risk of heart attack, failure: Study

Two diabetes medications increase risk of heart attack, failure: Study

Postmenopausal women with diabetes taking TZDs at increased fracture risk

Postmenopausal women with diabetes taking TZDs at increased fracture risk

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

New understanding on insulin resistance, action of diabetes drugs may lead to safer medication

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

American Heart Association comments on FDA advisory committee's rosiglitazone recommendations

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

JANUMET results in greater blood sugar reductions in patients with type 2 diabetes compared to pioglitazone

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx undertakes Phase II clinical trial of CCX140

ONGLYZA-metformin combination: FDA accepts NDA for review

ONGLYZA-metformin combination: FDA accepts NDA for review